# Cullinan Therapeutics Cullinan Therapeutics is an Asset Manager based in Cambridge, United States. ## Overview - **Organization type:** Asset Manager - **Headquarters:** Cambridge, United States - **Region:** North America - **Address:** Cambridge, MA, United States - **Founded:** 2017 - **Assets under management:** Undisclosed - **Website:** cullinantherapeutics.com ## Regulatory record - **Reports private funds:** No ## About Cullinan Therapeutics was founded in 2017 and previously operated as Cullinan Oncology, taking its name from the gemstone conglomerate to reflect its portfolio-of-assets architecture. The original model, conceived by founding CEO Owen Hughes and backers including F2 Ventures and MPM Capital, created independent subsidiaries — each a distinct legal entity with its own management and scientific focus — to advance oncology drug candidates in parallel. The firm raised over $600 million across private rounds and its 2021 initial public offering before consolidating its corporate structure under a unified pipeline and rebranding to Cullinan Therapeutics in 2024. The company develops targeted oncology and immunology therapies, with a lead asset in clinical trials for autoimmune diseases — a strategic pivot from pure oncology that the new brand was designed to encompass. Its pipeline spans bispecific T-cell engagers, monoclonal antibodies, and small-molecule programs. CLN-978, a CD19-directed T-cell engager, is in Phase 1 studies for systemic lupus erythematosus (per the firm's pipeline disclosures, 2025). A prior lead candidate, CLN-081, was licensed to Taiho Oncology in a deal that validated the model's ability to carve out and monetize single assets. The firm operates across the United States and collaborates with academic cancer centers and global contract research organizations for clinical execution. Corporate records show Cullinan employed roughly 85 professionals at the time of its 2024 strategic restructuring. The firm maintains its headquarters in Cambridge, Massachusetts — a dense biotech cluster — and has conducted clinical operations across sites in the United States, Europe, and Asia-Pacific. Jeffrey Trigilio, who joined as CFO in 2021, had previously steered finances at Akcea Therapeutics through its acquisition by Ionis Pharmaceuticals. January 2024: Nadim Ahmed was appointed President and CEO, replacing Owen Hughes; the firm simultaneously rebranded from Cullinan Oncology to Cullinan Therapeutics and announced a registered direct offering priced at-the-market for $25 million (per the firm, January 2024). The defining architectural feature is a disciplined capital-allocation system that originated with a decentralized subsidiary model and persists as a pipeline-rationalization mandate. Under Ahmed — who previously led the global CAR-T franchise at Bristol Myers Squibb and served as CEO of private biotech Umoja Biopharma — Cullinan has sharpened its focus to a concentrated set of immunology programs. This transition from incubation platform to therapeutic-focused company represents a different species of biotech that treats asset selection as a capital-markets function, not a R&D habit. ## Sectors - Biotechnology ## People - Nadim Ahmed — Chief Executive Officer - Jeffrey Trigilio — Chief Financial Officer - Jon Wigginton — President of R&D, Chief Medical Officer ## Questions ### Who runs investment and strategic decisions at Cullinan Therapeutics? Nadim Ahmed became President and CEO in January 2024, succeeding founding CEO Owen Hughes. Ahmed brings operational experience from leading the CAR-T franchise at Bristol Myers Squibb and serving as CEO of Umoja Biopharma. The board includes representatives from major venture backers such as F2 Ventures and MPM Capital, which have shaped the firm's capital-allocation discipline since its 2017 founding. ### How is Cullinan Therapeutics structured differently from a typical biotech? Originally founded on a hub-and-spoke model, Cullinan created independent subsidiary companies — each a legally separate entity with its own management team — to advance distinct oncology programs in parallel. This structure externalized risk and allowed rapid program termination without entangling pipeline-wide resources. Since the 2024 rebrand and CEO transition, the firm operates a more unified pipeline but retains the capital-discipline habits of its venture-studio origins. ### What is Cullinan's lead clinical program? CLN-978, a CD19-directed T-cell engager, is in Phase 1 clinical development for systemic lupus erythematosus, marking the firm's pivot from pure oncology into autoimmune disease. The company also advanced CLN-619, an anti-MICA/B monoclonal antibody, into clinical-stage development for solid tumors (per the firm's public pipeline disclosures). A prior candidate, CLN-081, was partnered with Taiho Oncology. ### Why did the company rebrand from Cullinan Oncology to Cullinan Therapeutics? The January 2024 rebrand coincided with Nadim Ahmed's appointment as CEO and signaled a strategic expansion beyond oncology into immunology and autoimmune indications. The name change reflects a pipeline that now includes programs targeting lupus and other autoimmune diseases while maintaining core oncology assets. The firm stated the new name better represents its broader therapeutic ambitions. ### Where does Cullinan Therapeutics source its drug candidates? Historically, Cullinan's subsidiary model enabled targeted asset acquisition and internal incubation. The firm sourced early-stage oncology candidates from academic partnerships and licensing agreements, then housed each in a dedicated legal entity. Under the consolidated structure, in-licensing and strategic partnerships remain core to pipeline build-out, though the firm has not publicly detailed specific sourcing arrangements for its current immunology programs. ## Related profiles - [Five Star Bancorp](https://altss.com/profile/five-star-bancorp) - [Trustco Bank Corp NY](https://altss.com/profile/trustco-bank-corp-n-y) --- Last updated: 2026-06-03T20:00:00.000Z Canonical page: https://altss.com/profile/cullinan-therapeutics-inc Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology